scholarly journals Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients

2015 ◽  
pp. 1123
Author(s):  
Paul Zarogoulidis ◽  
Kelly Domvri ◽  
Konstantinos Porpodis ◽  
Konstantinos Zarogoulidis ◽  
Alexandra Liaka ◽  
...  
Keyword(s):  
Phagocytic Activity ◽  
Phosphodiesterase 4 ◽  
Copd Patients

Effects of Piclamilast, a Selective Phosphodiesterase-4 Inhibitor, on Oxidative Burst of Sputum Cells From Mild Asthmatics and Stable COPD Patients

Lung ◽  
2004 ◽  
Vol 182 (6) ◽  
pp. 369-377 ◽  
Author(s):  
Kai M. Beeh ◽  
Jutta Beier ◽  
Claudia Lerch ◽  
Ann K. Schulz ◽  
Roland Buhl
Keyword(s):  
Oxidative Burst ◽  
Phosphodiesterase 4 ◽  
Copd Patients ◽  
Phosphodiesterase 4 Inhibitor

scholarly journals The use of roflumilast in COPD: a review

2015 ◽  
Vol 79 (3-4) ◽  
Author(s):  
Andrea Zanini ◽  
Francesca Cherubino ◽  
Patrizia Pignatti
Keyword(s):  
Lung Function ◽  
Treatment Options ◽  
Forced Expiratory Volume ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Phosphodiesterase 4 ◽  
Positive Effects ◽  
Exacerbation Frequency ◽  
Copd Patients ◽  
Significant Additive Effect

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Chronic inflammation and exacerbations play a central role in the progression of the disease. Currently, treatment options for COPD have been shown to improve the progressive decline in lung-function and/or decrease mortality rates. Roflumilast, a phosphodiesterase- 4 inhibitor, is an anti-inflammatory drug which has been licensed as an add-on therapy for COPD patients with forced expiratory volume in the first second <50% and frequent exacerbations. Clinical trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency. Roflumilast has a mechanism of action which allows it to obtain a significant additive effect to current therapeutic options for COPD patients. It is generally well tolerated, although the most common adverse effects include diarrhea, nausea, weight loss, and headache. This review article provides an overview of the positive effects of roflumilast on lung function, exacerbation frequency and glucose metabolism, and its interaction with concomitant inhaled treatments.

The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-α production in whole blood from COPD patients

2005 ◽  
Vol 18 (1) ◽  
pp. 49-54 ◽  
Author(s):  
M. Ouagued ◽  
C.A.E. Martin-Chouly ◽  
G. Brinchault ◽  
C. Leportier-Comoy ◽  
A. Depincé ◽  
...  
Keyword(s):  
Whole Blood ◽  
The Novel ◽  
Phosphodiesterase 4 ◽  
Copd Patients ◽  
Tnf Α ◽  
Phosphodiesterase 4 Inhibitor

scholarly journals Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations

2011 ◽  
Vol 5 ◽  
pp. CCRPM.S7049 ◽  
Author(s):  
Stephen K. Field
Keyword(s):  
Weight Loss ◽  
Lung Function ◽  
Fasting Blood Glucose ◽  
Pde4 Inhibitor ◽  
Rapid Decline ◽  
Phosphodiesterase 4 ◽  
Copd Patients ◽  
Increased Risk ◽  
History Of ◽  
Long Acting

Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD patients who require hospitalization will die in the subsequent year. Since many AECOPD require hospitalization, they account for most of the expense of caring for COPD patients. Treatment with long-acting bronchodilators and combination inhaled corticosteroid/long-acting bronchodilator inhalers reduces but does not eliminate AECOPD. Roflumilast, a selective phosphodiesterase 4 (PDE4) inhibitor, is an anti-inflammatory medication that improves lung function in patients with COPD. In patients with more severe airway obstruction, clinical features of chronic bronchitis, and a history of AECOPD, roflumilast reduces the frequency of AECOPD when given in combination with short-acting bronchodilators, long-acting bronchodilators, or inhaled corticosteroids. It is generally well tolerated but the most common adverse effects include diarrhea, nausea, weight loss, and headaches. In clinical trials, patients treated with roflumilast experienced weight loss that averaged just over 2 kg but was primarily due to the loss of fat tissue. Weight loss was least in underweight patients and obese patients experienced the greatest weight loss. An unexpected benefit of treatment with roflumilast was that fasting blood glucose and hemoglobin A1c levels improved in patients with comorbid type 2 diabetes mellitus. Roflumilast, the first selective PDE4 inhibitor to be marketed, is a promising drug for the management of COPD patients with more severe disease.

Oral and Oropharyngeal Sensory Function in Adults With Chronic Obstructive Pulmonary Disease

2020 ◽  
Vol 29 (2) ◽  
pp. 864-872
Author(s):  
Fernanda Borowsky da Rosa ◽  
Adriane Schmidt Pasqualoto ◽  
Catriona M. Steele ◽  
Renata Mancopes
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Oral Cavity ◽  
Pulmonary Disease ◽  
Thermal Sensation ◽  
Sensory Function ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Age Related ◽  
Copd Patients

Introduction The oral cavity and pharynx have a rich sensory system composed of specialized receptors. The integrity of oropharyngeal sensation is thought to be fundamental for safe and efficient swallowing. Chronic obstructive pulmonary disease (COPD) patients are at risk for oropharyngeal sensory impairment due to frequent use of inhaled medications and comorbidities including gastroesophageal reflux disease. Objective This study aimed to describe and compare oral and oropharyngeal sensory function measured using noninstrumental clinical methods in adults with COPD and healthy controls. Method Participants included 27 adults (18 men, nine women) with a diagnosis of COPD and a mean age of 66.56 years ( SD = 8.68). The control group comprised 11 healthy adults (five men, six women) with a mean age of 60.09 years ( SD = 11.57). Spirometry measures confirmed reduced functional expiratory volumes (% predicted) in the COPD patients compared to the control participants. All participants completed a case history interview and underwent clinical evaluation of oral and oropharyngeal sensation by a speech-language pathologist. The sensory evaluation explored the detection of tactile and temperature stimuli delivered by cotton swab to six locations in the oral cavity and two in the oropharynx as well as identification of the taste of stimuli administered in 5-ml boluses to the mouth. Analyses explored the frequencies of accurate responses regarding stimulus location, temperature and taste between groups, and between age groups (“≤ 65 years” and “> 65 years”) within the COPD cohort. Results We found significantly higher frequencies of reported use of inhaled medications ( p < .001) and xerostomia ( p = .003) in the COPD cohort. Oral cavity thermal sensation ( p = .009) was reduced in the COPD participants, and a significant age-related decline in gustatory sensation was found in the COPD group ( p = .018). Conclusion This study found that most of the measures of oral and oropharyngeal sensation remained intact in the COPD group. Oral thermal sensation was impaired in individuals with COPD, and reduced gustatory sensation was observed in the older COPD participants. Possible links between these results and the use of inhaled medication by individuals with COPD are discussed.

P. aeruginosa Worse Among Hospitalized COPD Patients

2006 ◽  
Vol 39 (11) ◽  
pp. 62
Author(s):  
PATRICE WENDLING
Keyword(s):  
Copd Patients
Sign in / Sign up

Export Citation Format

Share Document